What's in Collegium Medicum w Bydgoszczy's pipeline?

Collegium Medicum w Bydgoszczy has 10 drugs in our index: 9 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Collegium Medicum w Bydgoszczy's portfolio?

Top competitors by shared drug class: Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/collegium-medicum-w-bydgoszczy.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Collegium Medicum w Bydgoszczy — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Collegium Medicum w Bydgoszczy pipeline: 9 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Pulverized ticagrelor sublingually	Pulverized ticagrelor sublingually	marketed
Rosuvastatin and Ezetimibe morning or evening administration	Rosuvastatin and Ezetimibe morning or evening administration	marketed
Pulverized ticagrelor orally	Pulverized ticagrelor orally	marketed
Crushed ticagrelor, morphine,metoclopramide	Crushed ticagrelor, morphine,metoclopramide	marketed	Antiplatelet agent + opioid analgesic + antiemetic (combination therapy)	P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide)	Cardiovascular / Acute Coronary Syndrome with pain management
Crushed ticagrelor, morphine,naloxone	Crushed ticagrelor, morphine,naloxone	marketed	Antiplatelet agent + opioid + opioid antagonist combination	P2Y12 receptor (ticagrelor); mu opioid receptor (morphine); opioid receptors (naloxone antagonism)	Cardiovascular / Pain Management
Integral ticagrelor	Integral ticagrelor	marketed	P2Y12 platelet receptor antagonist	P2Y12 receptor	Cardiovascular
Ticagrelor followed with Morphine	Ticagrelor followed with Morphine	marketed	P2Y12 inhibitor (ticagrelor) + opioid analgesic (morphine)	P2Y12 receptor (ticagrelor); mu-opioid receptor (morphine)	Cardiovascular
Ticagrelor followed with Methoxyflurane	Ticagrelor followed with Methoxyflurane	marketed	Antiplatelet agent combined with volatile analgesic	P2Y12 receptor (ticagrelor); NMDA receptor and other targets (methoxyflurane)	Cardiovascular; Pain Management
Crushed ticagrelor followed by morphine	Crushed ticagrelor followed by morphine	marketed	P2Y12 receptor antagonist + opioid analgesic	P2Y12 receptor (ticagrelor); mu opioid receptor (morphine)	Cardiovascular

Therapeutic area mix

Cardiovascular · 3
Cardiovascular / Acute Coronary Syndrome with pain management · 1
Cardiovascular / Pain Management · 1
Cardiovascular; Pain Management · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Icahn School of Medicine at Mount Sinai · 1 shared drug class
Massachusetts General Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Collegium Medicum w Bydgoszczy:

Cite this brief

Drug Landscape (2026). Collegium Medicum w Bydgoszczy — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/collegium-medicum-w-bydgoszczy. Accessed 2026-05-17.